These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27373582)

  • 21. Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data.
    Cui L; He T; Jiang Y; Li M; Wang O; Jiajue R; Chi Y; Xu Q; Xing X; Xia W
    Osteoporos Int; 2020 Feb; 31(2):307-316. PubMed ID: 31754756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal.
    Marques A; Lourenço Ó; Ortsäter G; Borgström F; Kanis JA; da Silva JA
    Calcif Tissue Int; 2016 Aug; 99(2):131-41. PubMed ID: 27016370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale of the Spanish FRAX model in decision-making for predicting osteoporotic fractures: an update of FRIDEX cohort of Spanish women.
    Azagra R; Zwart M; Encabo G; Aguyé A; Martin-Sánchez JC; Puchol-Ruiz N; Gabriel-Escoda P; Ortiz-Alinque S; Gené E; Iglesias M; Moriña D; Diaz-Herrera MA; Utzet M; Manresa JM;
    BMC Musculoskelet Disord; 2016 Jun; 17():262. PubMed ID: 27317560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.
    Yoshizawa T; Nishino T; Okubo I; Yamazaki M
    Arch Osteoporos; 2018 Aug; 13(1):94. PubMed ID: 30159632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnitude of fragility fracture risk in the very old--are we meeting their needs? The Newcastle 85+ Study.
    Duncan R; Francis RM; Jagger C; Kingston A; McCloskey E; Collerton J; Robinson L; Kirkwood TB; Birrell F
    Osteoporos Int; 2015 Jan; 26(1):123-30. PubMed ID: 25224291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women.
    Yoshimura M; Moriwaki K; Noto S; Takiguchi T
    Osteoporos Int; 2017 Feb; 28(2):643-652. PubMed ID: 27743068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of applying the NOF, NOGG and Taiwanese guidelines to a cohort of Chinese early postmenopausal women.
    Cheung E; Kung AW; Tan KC
    Clin Endocrinol (Oxf); 2014 Feb; 80(2):200-7. PubMed ID: 24010883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effective osteoporosis treatment thresholds in Greece.
    Makras P; Athanasakis K; Boubouchairopoulou N; Rizou S; Anastasilakis AD; Kyriopoulos J; Lyritis GP
    Osteoporos Int; 2015 Jul; 26(7):1949-57. PubMed ID: 25740208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic evaluation of osteoporosis liaison service for secondary fracture prevention in postmenopausal osteoporosis patients with previous hip fracture in Japan.
    Moriwaki K; Noto S
    Osteoporos Int; 2017 Feb; 28(2):621-632. PubMed ID: 27699441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women.
    Mueller D; Gandjour A
    Appl Health Econ Health Policy; 2008; 6(2-3):113-35. PubMed ID: 19231905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of FRAX-based osteoporosis intervention using real world data.
    Goldshtein I; Ish-Shalom S; Leshno M
    Bone; 2017 Oct; 103():318-324. PubMed ID: 28778597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Assessment of a set of FRAX(®)-based criteria for the indication of bone densitometry in Spanish postmenopausal women].
    Gómez-Vaquero C; Roig-Vilaseca D; Bianchi M; Santo P; Narváez J; Nolla JM
    Med Clin (Barc); 2013 May; 140(10):439-43. PubMed ID: 22578993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fracture Risk Assessment Tool (FRAX®) Results Calculated With and Without Bone Mineral Density Values for the Evaluation of Fracture Risk in Postmenopausal Women With Osteopenia.
    Imerci A; Yalın Kılınç C; Aydogan NH; Karalezli MN; Savran A
    J Clin Densitom; 2018; 21(4):464-471. PubMed ID: 28781230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Osteoporotic fracture risk evaluation. Options when central densitometry is not available.
    Garduño-García Jde J; Pérez-Espejel I; Huitrón-Bravo G; Romero-Figueroa Mdel S
    Rev Med Inst Mex Seguro Soc; 2014; 52(6):674-9. PubMed ID: 25354062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fracture risk assessment tool (FRAX) and for the diagnosis of osteoporosis in Japanese middle-aged and elderly women: Chiba bone survey.
    Oka R; Ohira M; Suzuki S; Yoshida T; Koide H; Tanaka T; Tatsuno I
    Endocr J; 2018 Feb; 65(2):193-202. PubMed ID: 29151451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Agreement of Mexican FRAX with and without the value of bone mineral density in assessing the risk of fracture in daily clinical practice.
    Horta-Baas G; Pérez Bolde-Hernández A; Pérez-Pérez A; Vergara-Sánchez I; Romero-Figueroa MDS
    Med Clin (Barc); 2017 May; 148(9):387-393. PubMed ID: 28118961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-fracture care: do we need to educate patients rather than doctors? The PREVOST randomized controlled trial.
    Merle B; Chapurlat R; Vignot E; Thomas T; Haesebaert J; Schott AM
    Osteoporos Int; 2017 May; 28(5):1549-1558. PubMed ID: 28246884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managing osteoporosis with FRAX® in Australia: proposed new treatment thresholds from the 45&Up Study cohort.
    Chen JS; Simpson JM; Blyth FM; March LM
    Bone; 2014 Dec; 69():148-53. PubMed ID: 25263521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effective but clinically inappropriate: new NICE intervention thresholds in osteoporosis (Technology Appraisal 464).
    Harvey NC; McCloskey E; Kanis JA; Compston J; Cooper C
    Osteoporos Int; 2018 Jul; 29(7):1511-1513. PubMed ID: 29947864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of a fracture liaison service--a real-world evaluation after 6 years of service provision.
    Yong JH; Masucci L; Hoch JS; Sujic R; Beaton D
    Osteoporos Int; 2016 Jan; 27(1):231-40. PubMed ID: 26275439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.